Dissolution Incompatibility of Paracetamol as a Silent Dissolution Retardent Of Concomitantly Administered Drugs

dc.contributor.author	Yasarathna, K.
dc.contributor.author	Wijesinghe, C.
dc.contributor.author	Jayasuriya, B.
dc.contributor.author	Pathirana, W.
dc.date.accessioned	2018-11-16T05:13:48Z
dc.date.available	2018-11-16T05:13:48Z
dc.date.issued	2017
dc.identifier.citation	Pathirana, et al. ,"Dissolution Incompatibility of Paracetamol as a Silent Dissolution Retardent Of Concomitantly Administered Drugs", Int J Pharm 2017; 7(1): 38-49	en_US
dc.identifier.issn	2249-1848
dc.identifier.uri	http://dr.lib.sjp.ac.lk/handle/123456789/7508
dc.description.abstract	High strength tablets containing 500 mg or more active ingredients could affect the dissolution of concomitantly administered drugs. Dissolution of ten generic solid dosage forms was determined in the presence of sodium bicarbonate and paracetamol, 500 – 2250 mg. In a total of 111 dissolution tests 41 failed (37%) to meet the criteria. Where paracetamol was present 36 out of 50 end points failed (72%) with an extreme case in diltiazem tablets with 0% dissolution. Since longest test end points with failures mostly range from 60 – 90 minutes it is advisable to administer paracetamol 1.5 hours after other drugs in order to avoid potential pharmacokinetic disturbances.	en_US
dc.language.iso	en	en_US
dc.subject	Dissolution incompatibility, paracetamol, sodium bicarbonate, diltiazem.	en_US
dc.title	Dissolution Incompatibility of Paracetamol as a Silent Dissolution Retardent Of Concomitantly Administered Drugs	en_US
dc.type	Article	en_US